90824-33-2 Usage
General Description
Benzenesulfonamide, 2-hydrazino- (9CI) is a chemical compound with the molecular formula C6H8N4O2S. It is a sulfonamide derivative and contains a hydrazine group. Benzenesulfonamide, 2-hydrazino- (9CI) is used in organic synthesis and medicinal chemistry, particularly in the development of pharmaceuticals. It has been studied for its potential as an anti-cancer agent and as a therapeutic agent for autoimmune diseases. Additionally, it is also used as a precursor for the synthesis of other organic compounds and as a reagent in chemical reactions. Benzenesulfonamide, 2-hydrazino- (9CI) has applications in various fields and is a valuable building block for the synthesis of new and useful compounds.
Check Digit Verification of cas no
The CAS Registry Mumber 90824-33-2 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 9,0,8,2 and 4 respectively; the second part has 2 digits, 3 and 3 respectively.
Calculate Digit Verification of CAS Registry Number 90824-33:
(7*9)+(6*0)+(5*8)+(4*2)+(3*4)+(2*3)+(1*3)=132
132 % 10 = 2
So 90824-33-2 is a valid CAS Registry Number.
90824-33-2Relevant articles and documents
Discovery of potent, efficacious, and orally bioavailable inhibitors of blood coagulation factor Xa with neutral P1 moieties
Pinto, Donald J.P.,Galemmo Jr., Robert A.,Quan, Mimi L.,Orwat, Michael J.,Clark, Charles,Li, Renhua,Wells, Brian,Woerner, Francis,Alexander, Richard S.,Rossi, Karen A.,Smallwood, Angela,Wong, Pancras C.,Luettgen, Joseph M.,Rendina, Alan R.,Knabb, Robert M.,He, Kan,Wexler, Ruth R.,Lam, Patrick Y.S.
, p. 5584 - 5589 (2007/10/03)
The bicyclic dihydropyrazolopyridinone scaffold allowed for incorporation of multiple P1 moieties with subnanomolar binding affinities for blood coagulation factor Xa. The compound 3-[6-(2′-dimethylaminomethyl-biphenyl-4-yl)-7-oxo-3-trifluoro-methyl-4,5,6,7-tetrahydro-pyrazolo[3,4-c]pyridine-l-yl]-benzamide 6d shows good fXa potency, selectivity, in vivo efficacy and oral bioavailability. Compound 6d was selected for further pre-clinical evaluations.
